Your email has been successfully added to our mailing list.

×
-0.00654624803006428 -0.035034549642381 -0.0326100133349497 -0.0265486725663716 -0.0174566614135047 0.0122317856709903 0.0243665898896837 0.0364892714268396
Stock impact report

Breakthrough Results from Phase 2 Clinical Trial of Bermekimab in the Treatment of Atopic Dermatitis (AD) to be Presented on March 2, 2019 at American Academy of Dermatology Annual Meeting

XBiotech Inc. (XBIT)  More Company Research Source: GlobeNewswire
Last xbiotech inc. earnings: 8/9 03:01 pm Check Earnings Report
US:NASDAQ Investor Relations: xbiotech.com/about/investors.html
PDF Rapid and significant reduction in skin lesions, 66% (pEASI score in 4 and 7 weeks, respectively. Rapid and significant resolution of worst itch and pain, 57% (p Substantial mean reduction of worst itch and pain 71% (p AUSTIN, Texas, March 01, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that breakthrough results from its Phase 2 clinical trial of its antibody therapy, bermekimab, are being presented tomorrow at a late-breaking oral presentation during the annual meeting of the American Academy of Dermatology (AAD) being held  in Washington, DC. The presentation titled, “Bermekimab is a Rapid and Effective Treatment for Atopic Dermatitis (AD)” will take place on Saturday, March 2 at 1:10pmET in Ballroom A and will be presented by international dermatology expert, and lead researcher in the development of approved therapies for atopic dermatitis, Eric Simpson, M.D, M.C.R. Professor of Dermatology at Oregon Health & Science University, School of Medicine. The res [Read more]
Impact snapshot Event time: XBIT
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
XBIT alerts
from News Quantified
Opt-in for
XBIT alerts

from News Quantified
Opt-in for
XBIT alerts

from News Quantified